Drug Profile
Research programme: telomere signalling targeted agents - Pharminox
Alternative Names: PMX 500; PMX-000177; PMX-000177-761-785; RHPS4; TSTA - PharminoxLatest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator Cancer Research UK; University of Nottingham
- Developer Pharminox
- Class
- Mechanism of Action Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 Nov 2023 Pharmacodynamics data from preclinical trial in Cancer presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 07 Dec 2011 Research programme: telomere signalling targeted agents - Pharminox is available for licensing as of 07 Dec 2011. http://www.pharminox.com